Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Primary Health Care | 10 | 2022 | 350 | 4.010 |
Why?
|
Poisoning | 20 | 2023 | 42 | 3.150 |
Why?
|
Drug Overdose | 16 | 2023 | 70 | 2.810 |
Why?
|
Humans | 254 | 2024 | 88286 | 2.700 |
Why?
|
Physicians, Primary Care | 4 | 2024 | 105 | 2.260 |
Why?
|
Substance-Related Disorders | 13 | 2023 | 407 | 2.000 |
Why?
|
Toxicology | 6 | 2019 | 16 | 1.870 |
Why?
|
Cannabis | 3 | 2021 | 35 | 1.810 |
Why?
|
Pyrazoles | 6 | 2017 | 149 | 1.710 |
Why?
|
Musculoskeletal Diseases | 2 | 2023 | 34 | 1.690 |
Why?
|
Parkinson Disease | 3 | 2024 | 142 | 1.670 |
Why?
|
Eye Diseases | 2 | 2024 | 56 | 1.640 |
Why?
|
Sports Medicine | 2 | 2022 | 56 | 1.580 |
Why?
|
Antidotes | 8 | 2013 | 23 | 1.520 |
Why?
|
Private Practice | 3 | 2019 | 11 | 1.440 |
Why?
|
Emergency Service, Hospital | 21 | 2019 | 508 | 1.390 |
Why?
|
Carbon Monoxide Poisoning | 15 | 2009 | 18 | 1.370 |
Why?
|
Communicable Diseases | 4 | 2020 | 63 | 1.340 |
Why?
|
Lewy Body Disease | 2 | 2022 | 9 | 1.320 |
Why?
|
Emergencies | 11 | 2022 | 118 | 1.290 |
Why?
|
Occupational Exposure | 4 | 2022 | 81 | 1.250 |
Why?
|
Pyridones | 2 | 2017 | 53 | 1.150 |
Why?
|
Opioid-Related Disorders | 2 | 2020 | 178 | 1.070 |
Why?
|
Acetylcysteine | 3 | 2013 | 69 | 1.050 |
Why?
|
Methanol | 3 | 2015 | 12 | 1.030 |
Why?
|
Radiation Injuries | 4 | 2009 | 160 | 1.030 |
Why?
|
Child | 23 | 2024 | 7074 | 1.010 |
Why?
|
Dronabinol | 4 | 2021 | 56 | 0.970 |
Why?
|
Anemia, Sickle Cell | 3 | 2024 | 143 | 0.970 |
Why?
|
Muscular Diseases | 2 | 2023 | 64 | 0.960 |
Why?
|
Supranuclear Palsy, Progressive | 1 | 2024 | 21 | 0.950 |
Why?
|
Solvents | 4 | 2015 | 96 | 0.950 |
Why?
|
Suicide, Attempted | 15 | 2014 | 131 | 0.930 |
Why?
|
Burns, Chemical | 4 | 2014 | 12 | 0.920 |
Why?
|
Environmental Exposure | 4 | 2014 | 316 | 0.900 |
Why?
|
Dermatitis, Atopic | 1 | 2024 | 55 | 0.900 |
Why?
|
Antiviral Agents | 3 | 2020 | 514 | 0.880 |
Why?
|
Blood-Borne Pathogens | 1 | 2022 | 4 | 0.880 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2023 | 42 | 0.860 |
Why?
|
Diabetic Neuropathies | 1 | 2022 | 41 | 0.850 |
Why?
|
Delivery of Health Care | 2 | 2018 | 432 | 0.840 |
Why?
|
Polyneuropathies | 1 | 2022 | 27 | 0.840 |
Why?
|
Cardiology | 1 | 2023 | 113 | 0.830 |
Why?
|
Drug Labeling | 2 | 2013 | 41 | 0.830 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2023 | 110 | 0.830 |
Why?
|
Mouth Diseases | 1 | 2022 | 16 | 0.830 |
Why?
|
Cluster Headache | 1 | 2022 | 2 | 0.830 |
Why?
|
Malignant Carcinoid Syndrome | 1 | 2021 | 4 | 0.820 |
Why?
|
Scleroderma, Systemic | 1 | 2022 | 52 | 0.820 |
Why?
|
Tendinopathy | 1 | 2022 | 5 | 0.820 |
Why?
|
Acetaminophen | 3 | 2013 | 55 | 0.810 |
Why?
|
Stomatitis | 1 | 2021 | 30 | 0.810 |
Why?
|
Female | 79 | 2024 | 45560 | 0.810 |
Why?
|
Gastrointestinal Tract | 1 | 2024 | 190 | 0.800 |
Why?
|
Adult | 68 | 2023 | 26230 | 0.800 |
Why?
|
Male | 82 | 2023 | 41840 | 0.800 |
Why?
|
Carcinoid Tumor | 1 | 2021 | 43 | 0.800 |
Why?
|
Autoimmune Diseases | 1 | 2024 | 248 | 0.800 |
Why?
|
Health Equity | 1 | 2023 | 84 | 0.780 |
Why?
|
Genetic Therapy | 1 | 2024 | 357 | 0.780 |
Why?
|
Hypertension | 6 | 2019 | 725 | 0.770 |
Why?
|
Emergency Medicine | 7 | 2014 | 123 | 0.770 |
Why?
|
Plant Poisoning | 3 | 2016 | 6 | 0.760 |
Why?
|
United States | 24 | 2019 | 6857 | 0.760 |
Why?
|
Orbital Diseases | 1 | 2020 | 21 | 0.740 |
Why?
|
Emergency Treatment | 5 | 2014 | 43 | 0.740 |
Why?
|
Renal Insufficiency | 2 | 2011 | 102 | 0.730 |
Why?
|
Acne Vulgaris | 1 | 2020 | 35 | 0.730 |
Why?
|
Ethylene Glycol | 5 | 2011 | 6 | 0.730 |
Why?
|
Surgery, Plastic | 1 | 2020 | 42 | 0.730 |
Why?
|
Multiple Sclerosis | 1 | 2022 | 266 | 0.720 |
Why?
|
Liver Diseases | 2 | 2018 | 247 | 0.720 |
Why?
|
Pregnancy Complications | 3 | 2018 | 343 | 0.720 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 4 | 2019 | 201 | 0.700 |
Why?
|
Vaping | 1 | 2020 | 44 | 0.700 |
Why?
|
Health Services for Transgender Persons | 1 | 2019 | 2 | 0.700 |
Why?
|
Donor Selection | 1 | 2020 | 73 | 0.700 |
Why?
|
Pancreatitis | 1 | 2020 | 87 | 0.690 |
Why?
|
Hemorrhage | 3 | 2017 | 275 | 0.690 |
Why?
|
Contrast Media | 3 | 2021 | 1084 | 0.690 |
Why?
|
Child Welfare | 1 | 2019 | 39 | 0.680 |
Why?
|
Medical Marijuana | 1 | 2019 | 7 | 0.680 |
Why?
|
Miosis | 2 | 2014 | 10 | 0.680 |
Why?
|
Drainage | 1 | 2020 | 157 | 0.670 |
Why?
|
Electronic Nicotine Delivery Systems | 1 | 2020 | 72 | 0.670 |
Why?
|
Polonium | 2 | 2009 | 2 | 0.670 |
Why?
|
Intra-Abdominal Hypertension | 1 | 2019 | 5 | 0.670 |
Why?
|
Gender Identity | 1 | 2019 | 53 | 0.670 |
Why?
|
Physicians | 2 | 2018 | 684 | 0.660 |
Why?
|
Abdominal Cavity | 1 | 2019 | 18 | 0.660 |
Why?
|
Transsexualism | 1 | 2019 | 34 | 0.650 |
Why?
|
Homicide | 2 | 2009 | 43 | 0.650 |
Why?
|
Liver Failure, Acute | 1 | 2018 | 39 | 0.640 |
Why?
|
Pleural Effusion | 1 | 2018 | 47 | 0.640 |
Why?
|
Disease Management | 3 | 2019 | 328 | 0.640 |
Why?
|
Ethylene Glycols | 2 | 2012 | 10 | 0.630 |
Why?
|
Pressure | 1 | 2019 | 166 | 0.630 |
Why?
|
Illinois | 15 | 2020 | 465 | 0.630 |
Why?
|
Chemical and Drug Induced Liver Injury | 2 | 2011 | 68 | 0.630 |
Why?
|
Lung Diseases | 1 | 2020 | 268 | 0.630 |
Why?
|
Alzheimer Disease | 1 | 2022 | 482 | 0.620 |
Why?
|
Clonidine | 3 | 2009 | 33 | 0.620 |
Why?
|
Ephedra | 3 | 2015 | 3 | 0.610 |
Why?
|
Chemical Warfare Agents | 3 | 2009 | 7 | 0.600 |
Why?
|
Hypoglycemic Agents | 3 | 2011 | 344 | 0.600 |
Why?
|
Adrenergic alpha-Agonists | 2 | 2009 | 33 | 0.600 |
Why?
|
Administration, Oral | 8 | 2022 | 684 | 0.600 |
Why?
|
Metal-on-Metal Joint Prostheses | 2 | 2017 | 3 | 0.600 |
Why?
|
Resuscitation | 3 | 2014 | 105 | 0.600 |
Why?
|
Tissue Donors | 2 | 2020 | 494 | 0.600 |
Why?
|
Transgender Persons | 1 | 2019 | 99 | 0.590 |
Why?
|
Risk Factors | 15 | 2023 | 5430 | 0.590 |
Why?
|
Referral and Consultation | 3 | 2015 | 341 | 0.590 |
Why?
|
Chelation Therapy | 3 | 2007 | 3 | 0.590 |
Why?
|
Education, Medical, Continuing | 1 | 2018 | 105 | 0.590 |
Why?
|
Meconium | 6 | 1996 | 15 | 0.590 |
Why?
|
Ovarian Neoplasms | 1 | 2024 | 757 | 0.590 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 306 | 0.580 |
Why?
|
Hip Prosthesis | 2 | 2017 | 33 | 0.580 |
Why?
|
Review Literature as Topic | 3 | 2022 | 21 | 0.580 |
Why?
|
Gastroesophageal Reflux | 1 | 2019 | 121 | 0.580 |
Why?
|
Brain Injuries, Traumatic | 1 | 2019 | 88 | 0.570 |
Why?
|
Immunologic Factors | 1 | 2018 | 170 | 0.570 |
Why?
|
Teaching | 1 | 2018 | 147 | 0.570 |
Why?
|
Terrorism | 3 | 2009 | 9 | 0.570 |
Why?
|
Hypertension, Portal | 1 | 2016 | 47 | 0.570 |
Why?
|
Marijuana Abuse | 1 | 2016 | 26 | 0.570 |
Why?
|
Factor Xa Inhibitors | 1 | 2016 | 22 | 0.570 |
Why?
|
Organ Transplantation | 1 | 2020 | 274 | 0.560 |
Why?
|
Hypothermia | 2 | 2012 | 26 | 0.560 |
Why?
|
Dexmedetomidine | 1 | 2016 | 13 | 0.560 |
Why?
|
Adolescent | 23 | 2024 | 9125 | 0.560 |
Why?
|
Hepatorenal Syndrome | 1 | 2016 | 9 | 0.560 |
Why?
|
Analgesics, Opioid | 2 | 2017 | 435 | 0.550 |
Why?
|
Obesity | 1 | 2023 | 968 | 0.550 |
Why?
|
Medication Errors | 5 | 2011 | 39 | 0.550 |
Why?
|
Plants, Toxic | 1 | 2016 | 26 | 0.550 |
Why?
|
Venous Thromboembolism | 1 | 2018 | 158 | 0.550 |
Why?
|
Latex Hypersensitivity | 1 | 2015 | 1 | 0.540 |
Why?
|
Dermatitis, Allergic Contact | 1 | 2015 | 7 | 0.540 |
Why?
|
Patient Care Team | 1 | 2018 | 283 | 0.540 |
Why?
|
Physician Assistants | 1 | 2016 | 22 | 0.540 |
Why?
|
United States Food and Drug Administration | 3 | 2015 | 133 | 0.530 |
Why?
|
Delirium | 1 | 2016 | 72 | 0.530 |
Why?
|
Nurse Practitioners | 1 | 2016 | 31 | 0.530 |
Why?
|
Anaphylaxis | 1 | 2015 | 33 | 0.530 |
Why?
|
Metoclopramide | 2 | 2013 | 16 | 0.520 |
Why?
|
Accidents, Home | 2 | 2014 | 16 | 0.520 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2015 | 2 | 0.520 |
Why?
|
Arthroplasty, Replacement, Hip | 2 | 2017 | 101 | 0.520 |
Why?
|
Cholinesterase Inhibitors | 2 | 2014 | 45 | 0.520 |
Why?
|
Dopamine Antagonists | 2 | 2013 | 35 | 0.520 |
Why?
|
Analgesics, Non-Narcotic | 2 | 2013 | 47 | 0.520 |
Why?
|
Diabetes Mellitus | 1 | 2022 | 743 | 0.520 |
Why?
|
Inhalant Abuse | 1 | 2015 | 1 | 0.510 |
Why?
|
Headache Disorders | 1 | 2015 | 6 | 0.510 |
Why?
|
Psoriasis | 1 | 2018 | 245 | 0.510 |
Why?
|
Kidney Diseases | 1 | 2018 | 318 | 0.510 |
Why?
|
Irritants | 1 | 2014 | 4 | 0.500 |
Why?
|
Caustics | 1 | 2014 | 4 | 0.500 |
Why?
|
Urban Health Services | 1 | 2015 | 44 | 0.500 |
Why?
|
Hemostatic Disorders | 1 | 2014 | 1 | 0.500 |
Why?
|
Arrhythmias, Cardiac | 2 | 2014 | 195 | 0.490 |
Why?
|
Spices | 1 | 2014 | 1 | 0.490 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2021 | 1163 | 0.490 |
Why?
|
Tachycardia | 2 | 2013 | 37 | 0.490 |
Why?
|
Middle Aged | 46 | 2023 | 25571 | 0.490 |
Why?
|
Foodborne Diseases | 1 | 2014 | 8 | 0.480 |
Why?
|
Urinary Tract Infections | 1 | 2015 | 75 | 0.480 |
Why?
|
Anticonvulsants | 3 | 2008 | 125 | 0.480 |
Why?
|
Practice Patterns, Physicians' | 2 | 2013 | 597 | 0.480 |
Why?
|
Sexually Transmitted Diseases | 1 | 2016 | 96 | 0.480 |
Why?
|
Creatinine | 3 | 2011 | 295 | 0.480 |
Why?
|
Substance Abuse Detection | 3 | 2021 | 12 | 0.480 |
Why?
|
Seeds | 1 | 2014 | 49 | 0.480 |
Why?
|
Hydrocarbons | 1 | 2014 | 12 | 0.480 |
Why?
|
Cholinesterases | 1 | 2014 | 17 | 0.470 |
Why?
|
Phenylcarbamates | 1 | 2014 | 6 | 0.470 |
Why?
|
Pandemics | 1 | 2020 | 760 | 0.470 |
Why?
|
Neoplasms | 2 | 2022 | 2996 | 0.470 |
Why?
|
Bradycardia | 1 | 2014 | 39 | 0.470 |
Why?
|
Physical Examination | 2 | 2014 | 148 | 0.470 |
Why?
|
Bioterrorism | 3 | 2009 | 18 | 0.460 |
Why?
|
Indans | 1 | 2014 | 35 | 0.460 |
Why?
|
Chronic Pain | 1 | 2016 | 159 | 0.460 |
Why?
|
Prisoners | 1 | 2014 | 44 | 0.460 |
Why?
|
Thrombosis | 2 | 2016 | 301 | 0.460 |
Why?
|
Prosthesis Failure | 2 | 2017 | 114 | 0.450 |
Why?
|
Gastroparesis | 1 | 2013 | 14 | 0.450 |
Why?
|
Health Care Costs | 1 | 2015 | 233 | 0.430 |
Why?
|
Athletes | 2 | 2023 | 51 | 0.430 |
Why?
|
Cocaine | 7 | 1997 | 76 | 0.430 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 253 | 0.430 |
Why?
|
Stomach | 3 | 2009 | 110 | 0.430 |
Why?
|
Hip | 1 | 2012 | 18 | 0.430 |
Why?
|
Piperidines | 1 | 2014 | 163 | 0.420 |
Why?
|
Hearing Loss | 1 | 2013 | 58 | 0.420 |
Why?
|
Decontamination | 6 | 2014 | 10 | 0.420 |
Why?
|
Arthralgia | 1 | 2012 | 37 | 0.420 |
Why?
|
Designer Drugs | 1 | 2012 | 4 | 0.420 |
Why?
|
Environmental Monitoring | 4 | 2008 | 73 | 0.420 |
Why?
|
Hip Joint | 1 | 2012 | 54 | 0.410 |
Why?
|
Retrospective Studies | 18 | 2021 | 8836 | 0.410 |
Why?
|
Colitis, Ulcerative | 1 | 2019 | 723 | 0.410 |
Why?
|
Hypertension, Pulmonary | 1 | 2016 | 351 | 0.410 |
Why?
|
Methemoglobinemia | 3 | 2007 | 10 | 0.410 |
Why?
|
Insulin, Long-Acting | 1 | 2011 | 5 | 0.400 |
Why?
|
Insulin Lispro | 1 | 2011 | 3 | 0.400 |
Why?
|
2-Propanol | 1 | 2011 | 2 | 0.400 |
Why?
|
Asthma | 2 | 2019 | 972 | 0.400 |
Why?
|
Ethics, Medical | 1 | 2014 | 309 | 0.390 |
Why?
|
Amphotericin B | 1 | 2011 | 34 | 0.390 |
Why?
|
Child, Preschool | 14 | 2024 | 3667 | 0.390 |
Why?
|
Colonic Diseases | 1 | 2011 | 61 | 0.380 |
Why?
|
Insurance, Health, Reimbursement | 2 | 2015 | 60 | 0.380 |
Why?
|
Medical Order Entry Systems | 1 | 2011 | 25 | 0.380 |
Why?
|
Isoxazoles | 1 | 2011 | 78 | 0.380 |
Why?
|
Methamphetamine | 1 | 2012 | 84 | 0.370 |
Why?
|
Heart Arrest | 4 | 2002 | 268 | 0.370 |
Why?
|
Poison Control Centers | 5 | 2014 | 17 | 0.370 |
Why?
|
Drug Carriers | 1 | 2011 | 82 | 0.370 |
Why?
|
Risk Assessment | 5 | 2020 | 2281 | 0.370 |
Why?
|
Carbon Monoxide | 6 | 2000 | 93 | 0.370 |
Why?
|
Critical Care | 6 | 2014 | 377 | 0.370 |
Why?
|
Guillain-Barre Syndrome | 1 | 2010 | 16 | 0.360 |
Why?
|
Antifungal Agents | 1 | 2011 | 119 | 0.360 |
Why?
|
Cervical Vertebrae | 2 | 2009 | 80 | 0.360 |
Why?
|
Ammonium Chloride | 1 | 2009 | 22 | 0.360 |
Why?
|
Plasma Exchange | 1 | 2010 | 30 | 0.360 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 2402 | 0.360 |
Why?
|
Household Products | 1 | 2009 | 9 | 0.360 |
Why?
|
Arsenic Poisoning | 2 | 2007 | 103 | 0.360 |
Why?
|
Dystonia | 2 | 2008 | 29 | 0.360 |
Why?
|
Neck Pain | 1 | 2009 | 18 | 0.350 |
Why?
|
Treatment Outcome | 13 | 2017 | 8125 | 0.350 |
Why?
|
Radioactive Hazard Release | 2 | 2007 | 8 | 0.350 |
Why?
|
Carboxyhemoglobin | 10 | 1990 | 16 | 0.350 |
Why?
|
Muscle Weakness | 1 | 2010 | 60 | 0.350 |
Why?
|
Food Additives | 2 | 2000 | 2 | 0.350 |
Why?
|
Neonatal Abstinence Syndrome | 1 | 2009 | 6 | 0.350 |
Why?
|
Myocardial Infarction | 1 | 2013 | 372 | 0.350 |
Why?
|
Immunoglobulins | 1 | 2010 | 148 | 0.340 |
Why?
|
Attitude of Health Personnel | 1 | 2014 | 642 | 0.340 |
Why?
|
Syncope | 1 | 2009 | 34 | 0.340 |
Why?
|
Dry Ice | 1 | 2009 | 2 | 0.340 |
Why?
|
Confined Spaces | 1 | 2009 | 2 | 0.340 |
Why?
|
Asphyxia | 1 | 2009 | 11 | 0.340 |
Why?
|
Renal Dialysis | 4 | 2007 | 335 | 0.340 |
Why?
|
Chemical Terrorism | 1 | 2009 | 2 | 0.340 |
Why?
|
Biological Warfare Agents | 1 | 2009 | 3 | 0.340 |
Why?
|
Esophagus | 1 | 2009 | 107 | 0.340 |
Why?
|
Insecticides | 2 | 2008 | 27 | 0.330 |
Why?
|
Respiratory System | 1 | 2009 | 116 | 0.330 |
Why?
|
Lead Poisoning | 3 | 2004 | 10 | 0.330 |
Why?
|
Cosmetic Techniques | 1 | 2009 | 28 | 0.330 |
Why?
|
Myocarditis | 2 | 2000 | 52 | 0.330 |
Why?
|
Clinical Competence | 1 | 2014 | 779 | 0.330 |
Why?
|
Pyrethrins | 1 | 2008 | 10 | 0.320 |
Why?
|
Bronchiectasis | 1 | 2008 | 14 | 0.320 |
Why?
|
Stuttering | 1 | 2008 | 22 | 0.320 |
Why?
|
Gulf War | 1 | 2008 | 1 | 0.320 |
Why?
|
Nipecotic Acids | 1 | 2008 | 5 | 0.320 |
Why?
|
Atrial Fibrillation | 1 | 2013 | 345 | 0.320 |
Why?
|
Foscarnet | 1 | 2008 | 12 | 0.320 |
Why?
|
Acidosis | 2 | 2013 | 55 | 0.310 |
Why?
|
Mental Disorders | 2 | 2009 | 405 | 0.310 |
Why?
|
Status Epilepticus | 1 | 2008 | 33 | 0.310 |
Why?
|
Dermatology | 2 | 2018 | 37 | 0.310 |
Why?
|
Dapsone | 1 | 2007 | 10 | 0.310 |
Why?
|
Charcoal | 4 | 2005 | 13 | 0.310 |
Why?
|
Sleep Apnea Syndromes | 1 | 2009 | 105 | 0.310 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2008 | 78 | 0.300 |
Why?
|
Young Adult | 6 | 2023 | 6171 | 0.300 |
Why?
|
Aged | 23 | 2023 | 18834 | 0.300 |
Why?
|
Cross Infection | 1 | 2008 | 146 | 0.300 |
Why?
|
Mercury Poisoning | 1 | 2007 | 1 | 0.300 |
Why?
|
Mercuric Chloride | 1 | 2007 | 9 | 0.290 |
Why?
|
Breast Feeding | 1 | 2008 | 98 | 0.290 |
Why?
|
Evidence-Based Medicine | 2 | 2020 | 429 | 0.290 |
Why?
|
Postoperative Complications | 2 | 2018 | 2272 | 0.290 |
Why?
|
Bipolar Disorder | 1 | 2009 | 384 | 0.290 |
Why?
|
Oxides | 1 | 2007 | 43 | 0.290 |
Why?
|
Military Personnel | 1 | 2008 | 88 | 0.280 |
Why?
|
DEET | 2 | 1999 | 6 | 0.280 |
Why?
|
Anion Exchange Resins | 1 | 2006 | 1 | 0.280 |
Why?
|
Pfiesteria piscicida | 1 | 2006 | 1 | 0.280 |
Why?
|
Cholestyramine Resin | 1 | 2006 | 3 | 0.280 |
Why?
|
Protozoan Infections | 1 | 2006 | 3 | 0.280 |
Why?
|
Fatal Outcome | 3 | 2015 | 295 | 0.280 |
Why?
|
Acute Disease | 8 | 2014 | 838 | 0.270 |
Why?
|
Behavior, Addictive | 1 | 2008 | 133 | 0.270 |
Why?
|
History, 20th Century | 3 | 2020 | 308 | 0.270 |
Why?
|
Antipsychotic Agents | 2 | 2011 | 129 | 0.270 |
Why?
|
Gas Chromatography-Mass Spectrometry | 7 | 2008 | 42 | 0.270 |
Why?
|
Pediatrics | 2 | 2022 | 351 | 0.270 |
Why?
|
Protective Agents | 1 | 2006 | 33 | 0.270 |
Why?
|
Ischemia | 2 | 2006 | 251 | 0.270 |
Why?
|
Staphylococcal Infections | 1 | 2008 | 268 | 0.270 |
Why?
|
Leukemia | 1 | 2008 | 321 | 0.270 |
Why?
|
Time Factors | 10 | 2020 | 5299 | 0.270 |
Why?
|
Cobalt | 2 | 2017 | 30 | 0.260 |
Why?
|
Chromium | 2 | 2017 | 17 | 0.260 |
Why?
|
Administration, Topical | 5 | 2018 | 96 | 0.260 |
Why?
|
Diphenhydramine | 4 | 2008 | 17 | 0.260 |
Why?
|
Diarrhea | 1 | 2006 | 182 | 0.250 |
Why?
|
Infant, Newborn | 12 | 2009 | 2440 | 0.250 |
Why?
|
Alkalosis, Respiratory | 1 | 2004 | 4 | 0.240 |
Why?
|
Exchange Transfusion, Whole Blood | 1 | 2004 | 18 | 0.240 |
Why?
|
Petroleum | 2 | 2002 | 13 | 0.240 |
Why?
|
Emergency Medical Services | 2 | 2007 | 210 | 0.240 |
Why?
|
Hypnotics and Sedatives | 3 | 2016 | 130 | 0.240 |
Why?
|
Cardiovascular Diseases | 3 | 2018 | 703 | 0.240 |
Why?
|
Antidepressive Agents, Tricyclic | 2 | 2001 | 21 | 0.230 |
Why?
|
Hospitalization | 1 | 2009 | 868 | 0.230 |
Why?
|
Nuclear Warfare | 1 | 2003 | 4 | 0.230 |
Why?
|
Fat Emulsions, Intravenous | 1 | 2023 | 13 | 0.230 |
Why?
|
Therapeutic Irrigation | 4 | 2007 | 61 | 0.230 |
Why?
|
HIV Infections | 2 | 2014 | 825 | 0.230 |
Why?
|
Methylene Blue | 1 | 2003 | 18 | 0.230 |
Why?
|
Occupational Diseases | 2 | 2003 | 55 | 0.230 |
Why?
|
Combined Modality Therapy | 5 | 2014 | 1710 | 0.230 |
Why?
|
Alcohol Dehydrogenase | 1 | 2003 | 42 | 0.220 |
Why?
|
Blood Glucose | 4 | 2021 | 839 | 0.220 |
Why?
|
Leukemoid Reaction | 1 | 2002 | 5 | 0.220 |
Why?
|
Death, Sudden, Cardiac | 1 | 2023 | 48 | 0.220 |
Why?
|
Sodium Cyanide | 1 | 2002 | 6 | 0.220 |
Why?
|
Infant | 14 | 2003 | 3109 | 0.220 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2011 | 1943 | 0.220 |
Why?
|
Sorbitol | 2 | 2001 | 7 | 0.210 |
Why?
|
Substance Withdrawal Syndrome | 2 | 2016 | 46 | 0.210 |
Why?
|
Autopsy | 1 | 2003 | 121 | 0.210 |
Why?
|
Sympathomimetics | 2 | 2000 | 12 | 0.210 |
Why?
|
Cathartics | 2 | 2001 | 27 | 0.210 |
Why?
|
Metformin | 1 | 2004 | 122 | 0.210 |
Why?
|
Pharmaceutical Preparations | 4 | 2003 | 91 | 0.210 |
Why?
|
Infusions, Intravenous | 3 | 2013 | 430 | 0.210 |
Why?
|
Severity of Illness Index | 5 | 2010 | 1837 | 0.210 |
Why?
|
Age Factors | 3 | 2019 | 1855 | 0.210 |
Why?
|
Epinephrine | 4 | 1999 | 86 | 0.210 |
Why?
|
Influenza, Human | 2 | 2020 | 332 | 0.210 |
Why?
|
Toluene | 1 | 2002 | 5 | 0.210 |
Why?
|
Benzene | 1 | 2002 | 8 | 0.210 |
Why?
|
Hospital Units | 4 | 1995 | 30 | 0.210 |
Why?
|
Penile Induration | 1 | 2002 | 6 | 0.210 |
Why?
|
Mianserin | 1 | 2001 | 4 | 0.210 |
Why?
|
Vomiting | 2 | 2021 | 193 | 0.200 |
Why?
|
Pregnancy | 7 | 2018 | 2986 | 0.200 |
Why?
|
Risperidone | 1 | 2001 | 23 | 0.200 |
Why?
|
Internal Medicine | 2 | 2018 | 356 | 0.200 |
Why?
|
Cause of Death | 2 | 2020 | 270 | 0.200 |
Why?
|
Acidosis, Respiratory | 1 | 2001 | 7 | 0.200 |
Why?
|
Acetic Acid | 1 | 2001 | 8 | 0.190 |
Why?
|
History, 21st Century | 2 | 2020 | 177 | 0.190 |
Why?
|
Incidence | 3 | 2011 | 1587 | 0.190 |
Why?
|
Erectile Dysfunction | 1 | 2002 | 75 | 0.190 |
Why?
|
Liver | 2 | 2006 | 1238 | 0.190 |
Why?
|
Urban Health | 1 | 2001 | 56 | 0.190 |
Why?
|
Wisconsin | 1 | 2020 | 40 | 0.190 |
Why?
|
Diagnosis, Differential | 6 | 2011 | 1587 | 0.190 |
Why?
|
Mass Vaccination | 1 | 2020 | 9 | 0.180 |
Why?
|
Dermatitis, Occupational | 1 | 2000 | 2 | 0.180 |
Why?
|
Hearing Loss, Noise-Induced | 1 | 2000 | 4 | 0.180 |
Why?
|
Hallucinogens | 2 | 2014 | 77 | 0.180 |
Why?
|
Health Personnel | 1 | 2022 | 209 | 0.180 |
Why?
|
Suicide | 1 | 2002 | 150 | 0.180 |
Why?
|
Ibuprofen | 1 | 2000 | 27 | 0.180 |
Why?
|
Enzyme Inhibitors | 1 | 2003 | 645 | 0.180 |
Why?
|
Insect Repellents | 1 | 1999 | 3 | 0.180 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2000 | 242 | 0.180 |
Why?
|
Gentamicins | 1 | 1999 | 20 | 0.180 |
Why?
|
Rhabdomyolysis | 3 | 2003 | 28 | 0.180 |
Why?
|
Treatment Failure | 1 | 2020 | 289 | 0.170 |
Why?
|
Primidone | 1 | 1999 | 2 | 0.170 |
Why?
|
Back Pain | 1 | 1999 | 42 | 0.170 |
Why?
|
Chicago | 7 | 2015 | 1404 | 0.170 |
Why?
|
Outpatient Clinics, Hospital | 2 | 2013 | 23 | 0.170 |
Why?
|
Fentanyl | 1 | 1999 | 67 | 0.170 |
Why?
|
Current Procedural Terminology | 1 | 2019 | 12 | 0.170 |
Why?
|
Succimer | 3 | 2007 | 3 | 0.170 |
Why?
|
Russia | 2 | 2009 | 26 | 0.170 |
Why?
|
Legislation, Medical | 1 | 1999 | 10 | 0.170 |
Why?
|
Alkaloids | 1 | 1999 | 46 | 0.170 |
Why?
|
Plants, Medicinal | 1 | 1999 | 42 | 0.170 |
Why?
|
Hazardous Substances | 2 | 2014 | 7 | 0.160 |
Why?
|
Insurance Claim Review | 1 | 2019 | 46 | 0.160 |
Why?
|
Drug Hypersensitivity | 1 | 1999 | 37 | 0.160 |
Why?
|
Registries | 2 | 2020 | 750 | 0.160 |
Why?
|
Cross Reactions | 2 | 2015 | 109 | 0.160 |
Why?
|
Cocaine-Related Disorders | 1 | 1999 | 35 | 0.160 |
Why?
|
Genital Diseases, Female | 1 | 2018 | 24 | 0.160 |
Why?
|
Air Pollution, Indoor | 2 | 1998 | 63 | 0.160 |
Why?
|
Graft Survival | 2 | 2020 | 907 | 0.160 |
Why?
|
Patient Admission | 6 | 2009 | 113 | 0.160 |
Why?
|
New Orleans | 1 | 2018 | 6 | 0.160 |
Why?
|
Gastrointestinal Diseases | 2 | 2018 | 147 | 0.160 |
Why?
|
General Practice | 1 | 2018 | 9 | 0.160 |
Why?
|
Adrenergic beta-Antagonists | 1 | 1999 | 104 | 0.160 |
Why?
|
Cysteine | 1 | 1999 | 136 | 0.160 |
Why?
|
Brain Diseases | 1 | 1999 | 184 | 0.160 |
Why?
|
Professional Role | 1 | 2018 | 41 | 0.160 |
Why?
|
Urologic Diseases | 1 | 2018 | 45 | 0.160 |
Why?
|
Adverse Drug Reaction Reporting Systems | 2 | 2013 | 22 | 0.160 |
Why?
|
Lightning Injuries | 1 | 1997 | 2 | 0.160 |
Why?
|
Cerebrovascular Disorders | 1 | 1999 | 143 | 0.160 |
Why?
|
Phencyclidine | 2 | 1988 | 7 | 0.150 |
Why?
|
Geriatrics | 1 | 2018 | 63 | 0.150 |
Why?
|
Depressive Disorder | 1 | 2019 | 223 | 0.150 |
Why?
|
Joint Commission on Accreditation of Healthcare Organizations | 1 | 2017 | 13 | 0.150 |
Why?
|
Prognosis | 6 | 2010 | 3740 | 0.150 |
Why?
|
Neurology | 1 | 2018 | 70 | 0.150 |
Why?
|
Phenytoin | 2 | 1988 | 15 | 0.150 |
Why?
|
Crack Cocaine | 1 | 1997 | 3 | 0.150 |
Why?
|
Flumazenil | 2 | 1997 | 8 | 0.150 |
Why?
|
Disaster Planning | 3 | 2007 | 24 | 0.150 |
Why?
|
Epidemics | 1 | 2017 | 34 | 0.150 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2019 | 109 | 0.150 |
Why?
|
Vernix Caseosa | 1 | 1996 | 1 | 0.140 |
Why?
|
Fever | 1 | 1997 | 127 | 0.140 |
Why?
|
Half-Life | 1 | 2016 | 96 | 0.140 |
Why?
|
Hair | 1 | 1997 | 56 | 0.140 |
Why?
|
Administration, Intravenous | 1 | 2016 | 51 | 0.140 |
Why?
|
Marijuana Smoking | 1 | 2016 | 28 | 0.140 |
Why?
|
Prospective Studies | 6 | 2023 | 4257 | 0.140 |
Why?
|
Costs and Cost Analysis | 2 | 2015 | 155 | 0.140 |
Why?
|
Benzodiazepines | 3 | 2008 | 65 | 0.140 |
Why?
|
Drug Therapy, Combination | 3 | 2009 | 798 | 0.140 |
Why?
|
Education, Continuing | 2 | 2007 | 11 | 0.140 |
Why?
|
Insulin | 1 | 2021 | 1153 | 0.140 |
Why?
|
Atlases as Topic | 1 | 2016 | 8 | 0.140 |
Why?
|
Child Abuse | 1 | 1997 | 81 | 0.130 |
Why?
|
Gastroenterology | 1 | 2018 | 143 | 0.130 |
Why?
|
Epilepsy | 1 | 2000 | 416 | 0.130 |
Why?
|
Dimercaprol | 2 | 2007 | 6 | 0.130 |
Why?
|
Aged, 80 and over | 7 | 2013 | 6687 | 0.130 |
Why?
|
Drug Monitoring | 2 | 2011 | 119 | 0.130 |
Why?
|
Hydrocodone | 1 | 1995 | 7 | 0.130 |
Why?
|
Burns | 1 | 1997 | 139 | 0.130 |
Why?
|
Forensic Toxicology | 1 | 2015 | 1 | 0.130 |
Why?
|
Paint | 1 | 2015 | 4 | 0.130 |
Why?
|
Medicare | 1 | 2019 | 420 | 0.130 |
Why?
|
Disability Evaluation | 2 | 2010 | 138 | 0.130 |
Why?
|
Organic Chemicals | 1 | 2015 | 33 | 0.130 |
Why?
|
Medical History Taking | 2 | 2014 | 80 | 0.130 |
Why?
|
Movement Disorders | 2 | 2013 | 44 | 0.130 |
Why?
|
Circadian Rhythm | 3 | 1994 | 301 | 0.130 |
Why?
|
Narcotics | 2 | 2011 | 69 | 0.130 |
Why?
|
Acyclovir | 1 | 1995 | 107 | 0.120 |
Why?
|
Hospitals, Urban | 1 | 2015 | 55 | 0.120 |
Why?
|
Coma | 1 | 2015 | 44 | 0.120 |
Why?
|
Intubation, Intratracheal | 3 | 2000 | 145 | 0.120 |
Why?
|
Herpes Zoster | 1 | 1995 | 78 | 0.120 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 2014 | 16 | 0.120 |
Why?
|
Food Hypersensitivity | 1 | 2015 | 67 | 0.120 |
Why?
|
London | 2 | 2017 | 16 | 0.120 |
Why?
|
Seizures | 3 | 1997 | 302 | 0.120 |
Why?
|
Prisons | 1 | 2014 | 12 | 0.120 |
Why?
|
Rivastigmine | 1 | 2014 | 4 | 0.120 |
Why?
|
Follow-Up Studies | 4 | 2008 | 3655 | 0.120 |
Why?
|
Cost of Illness | 1 | 2015 | 148 | 0.120 |
Why?
|
Hypokalemia | 1 | 1994 | 23 | 0.120 |
Why?
|
Radiography, Abdominal | 1 | 1994 | 68 | 0.120 |
Why?
|
Physician's Role | 1 | 1996 | 176 | 0.120 |
Why?
|
Albuterol | 1 | 1994 | 35 | 0.120 |
Why?
|
Child Behavior | 1 | 2014 | 48 | 0.120 |
Why?
|
Occupational Health | 2 | 2007 | 33 | 0.120 |
Why?
|
Eye | 1 | 2014 | 111 | 0.110 |
Why?
|
Domperidone | 1 | 2013 | 8 | 0.110 |
Why?
|
Pharmacovigilance | 1 | 2013 | 3 | 0.110 |
Why?
|
Crotalid Venoms | 1 | 1993 | 2 | 0.110 |
Why?
|
Snake Bites | 1 | 1993 | 2 | 0.110 |
Why?
|
Antivenins | 1 | 1993 | 3 | 0.110 |
Why?
|
Ambulatory Care | 1 | 2015 | 185 | 0.110 |
Why?
|
Basidiomycota | 1 | 1993 | 10 | 0.110 |
Why?
|
Paraplegia | 1 | 1993 | 17 | 0.110 |
Why?
|
Streptococcus pyogenes | 1 | 1993 | 35 | 0.110 |
Why?
|
Heavy Metal Poisoning | 1 | 2013 | 1 | 0.110 |
Why?
|
Emergency Services, Psychiatric | 2 | 2007 | 12 | 0.110 |
Why?
|
Virginia | 1 | 2013 | 16 | 0.110 |
Why?
|
Patient Acceptance of Health Care | 2 | 2007 | 253 | 0.110 |
Why?
|
Adolescent Behavior | 1 | 2014 | 108 | 0.110 |
Why?
|
Respiration, Artificial | 2 | 2010 | 348 | 0.110 |
Why?
|
Metals, Heavy | 1 | 2013 | 15 | 0.110 |
Why?
|
Liability, Legal | 1 | 2013 | 32 | 0.110 |
Why?
|
Pharmacy Service, Hospital | 2 | 1992 | 9 | 0.110 |
Why?
|
Streptococcal Infections | 1 | 1993 | 57 | 0.110 |
Why?
|
Amyloidosis | 1 | 2014 | 124 | 0.110 |
Why?
|
Immunotherapy | 2 | 1991 | 655 | 0.110 |
Why?
|
Fluorescence Polarization Immunoassay | 4 | 1996 | 4 | 0.110 |
Why?
|
Hypoglycemia | 1 | 1993 | 105 | 0.100 |
Why?
|
Terpenes | 1 | 1992 | 17 | 0.100 |
Why?
|
Creatine Kinase | 2 | 1989 | 52 | 0.100 |
Why?
|
Immersion Foot | 1 | 2012 | 1 | 0.100 |
Why?
|
Cohort Studies | 2 | 2013 | 2827 | 0.100 |
Why?
|
Shock, Septic | 1 | 1993 | 104 | 0.100 |
Why?
|
Blood Pressure | 4 | 1991 | 885 | 0.100 |
Why?
|
Frostbite | 1 | 2012 | 8 | 0.100 |
Why?
|
Forecasting | 1 | 2013 | 305 | 0.100 |
Why?
|
Brain | 1 | 2022 | 2257 | 0.100 |
Why?
|
Insulin Glargine | 1 | 2011 | 9 | 0.100 |
Why?
|
Radiographic Image Enhancement | 1 | 1994 | 463 | 0.100 |
Why?
|
Droperidol | 1 | 2011 | 3 | 0.100 |
Why?
|
Hepatitis C | 1 | 2014 | 219 | 0.100 |
Why?
|
Prevalence | 3 | 2017 | 1245 | 0.100 |
Why?
|
Foreign Bodies | 2 | 2002 | 65 | 0.100 |
Why?
|
Labetalol | 1 | 1991 | 6 | 0.100 |
Why?
|
Nifedipine | 2 | 1991 | 25 | 0.100 |
Why?
|
Arsanilic Acid | 1 | 1991 | 1 | 0.100 |
Why?
|
September 11 Terrorist Attacks | 2 | 2008 | 2 | 0.100 |
Why?
|
Hypothermia, Induced | 1 | 2012 | 79 | 0.100 |
Why?
|
Periodicity | 1 | 1992 | 119 | 0.100 |
Why?
|
Chelating Agents | 2 | 2004 | 69 | 0.100 |
Why?
|
Methylene Chloride | 1 | 1990 | 2 | 0.100 |
Why?
|
Prescription Drugs | 1 | 2011 | 36 | 0.100 |
Why?
|
Methadone | 1 | 2011 | 44 | 0.100 |
Why?
|
Liposomes | 1 | 2011 | 92 | 0.100 |
Why?
|
Diagnosis, Dual (Psychiatry) | 2 | 2007 | 17 | 0.090 |
Why?
|
Kidney Failure, Chronic | 1 | 1995 | 412 | 0.090 |
Why?
|
Bilirubin | 1 | 2011 | 130 | 0.090 |
Why?
|
Regional Medical Programs | 1 | 1990 | 5 | 0.090 |
Why?
|
Schools, Medical | 1 | 1992 | 133 | 0.090 |
Why?
|
Electrocardiography | 6 | 2001 | 495 | 0.090 |
Why?
|
Nalbuphine | 1 | 1990 | 3 | 0.090 |
Why?
|
Morphinans | 1 | 1990 | 4 | 0.090 |
Why?
|
Meperidine | 1 | 1990 | 13 | 0.090 |
Why?
|
Respiratory Insufficiency | 1 | 1992 | 159 | 0.090 |
Why?
|
Epiglottitis | 1 | 1990 | 1 | 0.090 |
Why?
|
Laryngitis | 1 | 1990 | 2 | 0.090 |
Why?
|
Anthrax | 2 | 2008 | 30 | 0.090 |
Why?
|
Parotitis | 1 | 1990 | 6 | 0.090 |
Why?
|
Trauma Centers | 2 | 1990 | 132 | 0.090 |
Why?
|
Clinical Protocols | 1 | 1991 | 157 | 0.090 |
Why?
|
Liver Abscess | 1 | 1990 | 12 | 0.090 |
Why?
|
Intestines | 2 | 2005 | 415 | 0.090 |
Why?
|
Multiple Myeloma | 1 | 2014 | 323 | 0.090 |
Why?
|
Muscle Relaxants, Central | 1 | 1990 | 10 | 0.090 |
Why?
|
Electroencephalography | 1 | 2015 | 740 | 0.090 |
Why?
|
Nitroglycerin | 1 | 1990 | 23 | 0.090 |
Why?
|
Neurosurgery | 1 | 2011 | 94 | 0.090 |
Why?
|
Ethanol | 1 | 1992 | 250 | 0.090 |
Why?
|
Survival Rate | 2 | 2010 | 1881 | 0.090 |
Why?
|
Gastroscopy | 1 | 2009 | 24 | 0.090 |
Why?
|
Digoxin | 2 | 1990 | 21 | 0.090 |
Why?
|
Muscles | 1 | 1990 | 193 | 0.090 |
Why?
|
Electromyography | 1 | 2010 | 192 | 0.090 |
Why?
|
Administration, Inhalation | 2 | 2002 | 188 | 0.090 |
Why?
|
Tissue and Organ Procurement | 1 | 1994 | 339 | 0.090 |
Why?
|
Causality | 1 | 2009 | 80 | 0.090 |
Why?
|
Survival Analysis | 1 | 2013 | 1542 | 0.080 |
Why?
|
Esophagoscopy | 1 | 2009 | 89 | 0.080 |
Why?
|
Automobiles | 1 | 2009 | 13 | 0.080 |
Why?
|
Weapons of Mass Destruction | 1 | 2009 | 2 | 0.080 |
Why?
|
Population Surveillance | 2 | 2001 | 217 | 0.080 |
Why?
|
Polyarteritis Nodosa | 1 | 1988 | 7 | 0.080 |
Why?
|
Central Nervous System Stimulants | 1 | 2012 | 217 | 0.080 |
Why?
|
Quality Improvement | 1 | 2013 | 440 | 0.080 |
Why?
|
Mesoridazine | 1 | 1988 | 1 | 0.080 |
Why?
|
Software | 1 | 1993 | 661 | 0.080 |
Why?
|
Aspergillosis, Allergic Bronchopulmonary | 1 | 2008 | 7 | 0.080 |
Why?
|
Lice Infestations | 1 | 2008 | 3 | 0.080 |
Why?
|
Education, Medical | 1 | 1992 | 243 | 0.080 |
Why?
|
Immunoglobulin Fab Fragments | 2 | 1990 | 82 | 0.080 |
Why?
|
Motor Skills Disorders | 1 | 2008 | 15 | 0.080 |
Why?
|
Administration, Cutaneous | 1 | 2008 | 60 | 0.080 |
Why?
|
Pneumonia, Bacterial | 1 | 2008 | 29 | 0.080 |
Why?
|
Mycobacterium Infections, Nontuberculous | 1 | 2008 | 26 | 0.080 |
Why?
|
Heart Diseases | 2 | 1993 | 297 | 0.080 |
Why?
|
Neuroleptic Malignant Syndrome | 1 | 1988 | 3 | 0.080 |
Why?
|
Milk, Human | 1 | 2008 | 44 | 0.080 |
Why?
|
Cholinergic Antagonists | 1 | 2008 | 26 | 0.080 |
Why?
|
Abdomen | 1 | 1988 | 121 | 0.080 |
Why?
|
Gestational Age | 1 | 2009 | 321 | 0.080 |
Why?
|
Military Medicine | 1 | 2008 | 20 | 0.080 |
Why?
|
Botulinum Toxins | 2 | 2005 | 17 | 0.080 |
Why?
|
Bronchoscopy | 1 | 2009 | 157 | 0.080 |
Why?
|
Skin Absorption | 2 | 2004 | 4 | 0.080 |
Why?
|
Colon | 1 | 2011 | 502 | 0.080 |
Why?
|
Health Facility Closure | 1 | 1988 | 7 | 0.080 |
Why?
|
Europe | 1 | 2008 | 313 | 0.080 |
Why?
|
Potassium | 2 | 1988 | 252 | 0.080 |
Why?
|
Cytomegalovirus | 1 | 2008 | 78 | 0.080 |
Why?
|
Viremia | 1 | 2008 | 56 | 0.080 |
Why?
|
Total Quality Management | 1 | 2007 | 33 | 0.080 |
Why?
|
Sodium Bicarbonate | 1 | 2007 | 10 | 0.080 |
Why?
|
Bacillus anthracis | 1 | 2008 | 73 | 0.080 |
Why?
|
Propofol | 1 | 2008 | 91 | 0.080 |
Why?
|
Health Facilities | 1 | 1988 | 36 | 0.080 |
Why?
|
Epilepsy, Generalized | 1 | 2008 | 40 | 0.080 |
Why?
|
Powders | 1 | 2008 | 77 | 0.070 |
Why?
|
Antibodies | 2 | 1991 | 354 | 0.070 |
Why?
|
Sodium Chloride | 1 | 2007 | 87 | 0.070 |
Why?
|
Cystic Fibrosis | 1 | 2008 | 117 | 0.070 |
Why?
|
Dizziness | 3 | 2001 | 26 | 0.070 |
Why?
|
Benchmarking | 1 | 2007 | 79 | 0.070 |
Why?
|
Global Health | 1 | 2008 | 185 | 0.070 |
Why?
|
Ciguatera Poisoning | 1 | 1987 | 1 | 0.070 |
Why?
|
Marine Toxins | 1 | 1987 | 7 | 0.070 |
Why?
|
Amitriptyline | 1 | 1987 | 11 | 0.070 |
Why?
|
Kidney Transplantation | 1 | 1994 | 849 | 0.070 |
Why?
|
Chorea | 1 | 2006 | 12 | 0.070 |
Why?
|
Dyskinesia, Drug-Induced | 1 | 2006 | 19 | 0.070 |
Why?
|
Arsenicals | 1 | 2007 | 48 | 0.070 |
Why?
|
Atropine | 1 | 1986 | 60 | 0.070 |
Why?
|
Equipment Failure | 2 | 1998 | 120 | 0.070 |
Why?
|
Analysis of Variance | 2 | 2002 | 901 | 0.070 |
Why?
|
Amphetamines | 2 | 1997 | 18 | 0.070 |
Why?
|
Puerperal Disorders | 1 | 1986 | 32 | 0.070 |
Why?
|
Antisocial Personality Disorder | 1 | 2007 | 92 | 0.070 |
Why?
|
Lung Diseases, Obstructive | 1 | 1986 | 19 | 0.070 |
Why?
|
Anxiety Disorders | 1 | 2007 | 151 | 0.070 |
Why?
|
Pneumonia | 2 | 1990 | 183 | 0.070 |
Why?
|
Drug Prescriptions | 1 | 2007 | 144 | 0.070 |
Why?
|
Radiation Dosage | 2 | 2003 | 226 | 0.070 |
Why?
|
Liver Transplantation | 1 | 1994 | 1290 | 0.070 |
Why?
|
Leukocytosis | 1 | 1985 | 16 | 0.060 |
Why?
|
Autonomic Nervous System Diseases | 1 | 2005 | 22 | 0.060 |
Why?
|
Hemoglobins | 1 | 1986 | 189 | 0.060 |
Why?
|
Theophylline | 1 | 1985 | 33 | 0.060 |
Why?
|
Antidepressive Agents | 1 | 2006 | 111 | 0.060 |
Why?
|
Naloxone | 1 | 2005 | 64 | 0.060 |
Why?
|
Vision Disorders | 1 | 2005 | 74 | 0.060 |
Why?
|
Animals | 7 | 2009 | 27127 | 0.060 |
Why?
|
Disease Progression | 1 | 2009 | 1488 | 0.060 |
Why?
|
Polyethylene Glycols | 1 | 2007 | 365 | 0.060 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 1986 | 208 | 0.060 |
Why?
|
Ceramics | 1 | 2004 | 1 | 0.060 |
Why?
|
Pica | 1 | 2004 | 14 | 0.060 |
Why?
|
Edetic Acid | 1 | 2004 | 42 | 0.060 |
Why?
|
Seasons | 5 | 2001 | 233 | 0.060 |
Why?
|
Jurisprudence | 1 | 2004 | 25 | 0.060 |
Why?
|
Arum | 1 | 2003 | 2 | 0.060 |
Why?
|
Laryngeal Edema | 1 | 2003 | 7 | 0.060 |
Why?
|
Diagnosis | 2 | 1995 | 18 | 0.060 |
Why?
|
Aggression | 1 | 1988 | 323 | 0.060 |
Why?
|
Neurotoxicity Syndromes | 1 | 2004 | 28 | 0.060 |
Why?
|
Inhalation Exposure | 1 | 2004 | 30 | 0.060 |
Why?
|
Facial Nerve Diseases | 1 | 2003 | 3 | 0.060 |
Why?
|
Nuclear Reactors | 1 | 2003 | 8 | 0.060 |
Why?
|
Narcotic Antagonists | 1 | 2005 | 157 | 0.060 |
Why?
|
Postmortem Changes | 1 | 2003 | 8 | 0.060 |
Why?
|
Radiation, Ionizing | 1 | 2003 | 121 | 0.060 |
Why?
|
Pharmacokinetics | 1 | 2003 | 10 | 0.060 |
Why?
|
Intestinal Absorption | 1 | 2003 | 124 | 0.050 |
Why?
|
Soman | 1 | 2002 | 1 | 0.050 |
Why?
|
Organophosphate Poisoning | 1 | 2002 | 2 | 0.050 |
Why?
|
Sarin | 1 | 2002 | 2 | 0.050 |
Why?
|
Histamine H1 Antagonists | 1 | 2003 | 40 | 0.050 |
Why?
|
Organophosphates | 1 | 2002 | 6 | 0.050 |
Why?
|
Thiosulfates | 1 | 2002 | 3 | 0.050 |
Why?
|
Organothiophosphorus Compounds | 1 | 2002 | 17 | 0.050 |
Why?
|
Airway Obstruction | 1 | 2003 | 110 | 0.050 |
Why?
|
Tissue Distribution | 1 | 2003 | 292 | 0.050 |
Why?
|
Hospitals, University | 3 | 2011 | 195 | 0.050 |
Why?
|
Ultraviolet Rays | 1 | 2003 | 193 | 0.050 |
Why?
|
Trichloroethylene | 1 | 2002 | 1 | 0.050 |
Why?
|
Chemical Warfare | 1 | 2002 | 2 | 0.050 |
Why?
|
Biological Warfare | 1 | 2002 | 6 | 0.050 |
Why?
|
Industry | 1 | 2002 | 17 | 0.050 |
Why?
|
Nervous System | 1 | 2002 | 87 | 0.050 |
Why?
|
Amnesia | 1 | 2002 | 14 | 0.050 |
Why?
|
Acid-Base Equilibrium | 1 | 2002 | 32 | 0.050 |
Why?
|
Hallucinations | 2 | 1995 | 29 | 0.050 |
Why?
|
Mucous Membrane | 1 | 2001 | 83 | 0.050 |
Why?
|
Reproducibility of Results | 3 | 1998 | 2742 | 0.050 |
Why?
|
Antidepressive Agents, Second-Generation | 2 | 1999 | 19 | 0.050 |
Why?
|
Chest Pain | 1 | 2001 | 43 | 0.050 |
Why?
|
Journalism | 1 | 2001 | 2 | 0.050 |
Why?
|
Brain Death | 1 | 2002 | 80 | 0.050 |
Why?
|
Protective Devices | 1 | 2001 | 8 | 0.050 |
Why?
|
Aerosols | 1 | 2001 | 44 | 0.050 |
Why?
|
Anesthetics, Inhalation | 1 | 2002 | 95 | 0.050 |
Why?
|
Information Services | 1 | 2001 | 23 | 0.050 |
Why?
|
Fatigue | 1 | 2001 | 178 | 0.050 |
Why?
|
Critical Illness | 1 | 2023 | 304 | 0.050 |
Why?
|
United States Occupational Safety and Health Administration | 1 | 2000 | 1 | 0.050 |
Why?
|
Maximum Allowable Concentration | 1 | 2000 | 2 | 0.050 |
Why?
|
Noise, Occupational | 1 | 2000 | 2 | 0.050 |
Why?
|
Workers' Compensation | 1 | 2000 | 4 | 0.050 |
Why?
|
Colonoscopy | 1 | 2002 | 273 | 0.040 |
Why?
|
Epidemiological Monitoring | 1 | 2000 | 39 | 0.040 |
Why?
|
Meclizine | 1 | 1999 | 1 | 0.040 |
Why?
|
Benztropine | 1 | 1999 | 4 | 0.040 |
Why?
|
Communicable Disease Control | 1 | 2000 | 50 | 0.040 |
Why?
|
Radiography | 4 | 1990 | 810 | 0.040 |
Why?
|
Neurologic Examination | 1 | 1999 | 119 | 0.040 |
Why?
|
Injections, Intravenous | 2 | 1991 | 241 | 0.040 |
Why?
|
Analgesia, Epidural | 1 | 1999 | 38 | 0.040 |
Why?
|
Regression Analysis | 4 | 1994 | 594 | 0.040 |
Why?
|
Propranolol | 1 | 1999 | 44 | 0.040 |
Why?
|
Potassium Permanganate | 1 | 1998 | 2 | 0.040 |
Why?
|
Eye Burns | 1 | 1998 | 5 | 0.040 |
Why?
|
Headache | 3 | 1988 | 72 | 0.040 |
Why?
|
Polypharmacy | 1 | 1999 | 14 | 0.040 |
Why?
|
Terbutaline | 1 | 1999 | 16 | 0.040 |
Why?
|
Triazoles | 1 | 1999 | 100 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 1 | 1999 | 105 | 0.040 |
Why?
|
Ascorbic Acid | 1 | 1998 | 38 | 0.040 |
Why?
|
Thumb | 1 | 1999 | 22 | 0.040 |
Why?
|
Crystallization | 1 | 1999 | 209 | 0.040 |
Why?
|
Adrenergic beta-Agonists | 1 | 1999 | 72 | 0.040 |
Why?
|
3-Hydroxybutyric Acid | 1 | 1998 | 7 | 0.040 |
Why?
|
Arm | 1 | 1999 | 96 | 0.040 |
Why?
|
Diabetic Ketoacidosis | 1 | 1998 | 14 | 0.040 |
Why?
|
Sex Factors | 2 | 1994 | 1060 | 0.040 |
Why?
|
Patient Transfer | 2 | 1996 | 94 | 0.040 |
Why?
|
Rewarming | 1 | 1997 | 5 | 0.040 |
Why?
|
Smoke Inhalation Injury | 1 | 1997 | 7 | 0.040 |
Why?
|
Prenatal Exposure Delayed Effects | 2 | 1996 | 157 | 0.040 |
Why?
|
Cyclohexanols | 1 | 1997 | 7 | 0.040 |
Why?
|
Heat Stress Disorders | 1 | 1997 | 11 | 0.040 |
Why?
|
Toluidines | 1 | 1997 | 18 | 0.040 |
Why?
|
Cosmetics | 1 | 1997 | 7 | 0.040 |
Why?
|
Curriculum | 2 | 1992 | 564 | 0.040 |
Why?
|
Triazines | 1 | 1997 | 53 | 0.040 |
Why?
|
Household Articles | 1 | 1997 | 15 | 0.040 |
Why?
|
Wounds and Injuries | 2 | 1990 | 251 | 0.040 |
Why?
|
Chromatography, Gas | 1 | 1996 | 28 | 0.040 |
Why?
|
Delayed-Action Preparations | 2 | 1994 | 111 | 0.040 |
Why?
|
Umbilical Cord | 1 | 1996 | 40 | 0.040 |
Why?
|
Cluster Analysis | 1 | 1997 | 371 | 0.040 |
Why?
|
Tachycardia, Ventricular | 1 | 1997 | 120 | 0.040 |
Why?
|
Hospitals, Psychiatric | 1 | 1996 | 23 | 0.030 |
Why?
|
Reference Standards | 1 | 1996 | 143 | 0.030 |
Why?
|
Enzyme Multiplied Immunoassay Technique | 1 | 1995 | 1 | 0.030 |
Why?
|
Codeine | 1 | 1995 | 12 | 0.030 |
Why?
|
Hydromorphone | 1 | 1995 | 11 | 0.030 |
Why?
|
False Negative Reactions | 1 | 1995 | 63 | 0.030 |
Why?
|
Materials Testing | 1 | 1996 | 93 | 0.030 |
Why?
|
Pregnancy, Multiple | 1 | 1995 | 37 | 0.030 |
Why?
|
Hydrolysis | 1 | 1995 | 142 | 0.030 |
Why?
|
Odds Ratio | 1 | 2017 | 684 | 0.030 |
Why?
|
False Positive Reactions | 1 | 1995 | 222 | 0.030 |
Why?
|
Myoclonus | 1 | 1995 | 16 | 0.030 |
Why?
|
Program Evaluation | 1 | 1997 | 302 | 0.030 |
Why?
|
Blood Chemical Analysis | 1 | 1995 | 42 | 0.030 |
Why?
|
Mass Screening | 1 | 2000 | 631 | 0.030 |
Why?
|
Pyridines | 1 | 1997 | 316 | 0.030 |
Why?
|
Ataxia | 1 | 1995 | 39 | 0.030 |
Why?
|
Morphine | 1 | 1995 | 130 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 1995 | 1042 | 0.030 |
Why?
|
Psychiatric Status Rating Scales | 1 | 1996 | 491 | 0.030 |
Why?
|
Nausea | 1 | 1995 | 176 | 0.030 |
Why?
|
Emergency Nursing | 1 | 1993 | 7 | 0.030 |
Why?
|
Personnel Staffing and Scheduling | 2 | 1992 | 93 | 0.030 |
Why?
|
Memory | 1 | 1995 | 223 | 0.030 |
Why?
|
Heart Conduction System | 1 | 1993 | 112 | 0.030 |
Why?
|
Waiting Lists | 1 | 1994 | 188 | 0.030 |
Why?
|
Erythrocytes | 1 | 1993 | 254 | 0.030 |
Why?
|
Pharmacology | 1 | 1992 | 11 | 0.030 |
Why?
|
Specialization | 1 | 1992 | 65 | 0.030 |
Why?
|
Observation | 2 | 2002 | 38 | 0.030 |
Why?
|
Certification | 1 | 1992 | 61 | 0.030 |
Why?
|
Bacteremia | 1 | 1993 | 102 | 0.030 |
Why?
|
Diazepam | 1 | 1992 | 28 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 1999 | 2331 | 0.030 |
Why?
|
Pathology | 1 | 1992 | 32 | 0.030 |
Why?
|
Medicine | 1 | 1992 | 90 | 0.030 |
Why?
|
Drug Combinations | 1 | 1992 | 202 | 0.020 |
Why?
|
Canada | 1 | 1992 | 205 | 0.020 |
Why?
|
Cardiolipins | 1 | 1991 | 17 | 0.020 |
Why?
|
Furosemide | 1 | 1991 | 33 | 0.020 |
Why?
|
Biomarkers | 1 | 2017 | 1753 | 0.020 |
Why?
|
Drug Therapy | 1 | 1991 | 70 | 0.020 |
Why?
|
Ovalbumin | 1 | 1991 | 109 | 0.020 |
Why?
|
Respiratory Tract Diseases | 1 | 1990 | 45 | 0.020 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 1993 | 192 | 0.020 |
Why?
|
Tracheotomy | 1 | 1990 | 18 | 0.020 |
Why?
|
Chronobiology Phenomena | 1 | 1990 | 4 | 0.020 |
Why?
|
Alcoholism | 1 | 1992 | 175 | 0.020 |
Why?
|
Remission, Spontaneous | 1 | 1990 | 53 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2000 | 2629 | 0.020 |
Why?
|
Computer Simulation | 1 | 1994 | 1095 | 0.020 |
Why?
|
Faculty, Medical | 1 | 1992 | 183 | 0.020 |
Why?
|
Systole | 1 | 1990 | 109 | 0.020 |
Why?
|
Diastole | 1 | 1990 | 134 | 0.020 |
Why?
|
Thiocyanates | 1 | 1989 | 11 | 0.020 |
Why?
|
Blood Gas Analysis | 1 | 1989 | 38 | 0.020 |
Why?
|
Ultrasonography | 1 | 1992 | 703 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 1990 | 360 | 0.020 |
Why?
|
Quality of Health Care | 1 | 1992 | 383 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 1990 | 157 | 0.020 |
Why?
|
Spectrophotometry, Infrared | 1 | 2008 | 18 | 0.020 |
Why?
|
Chemistry, Analytic | 1 | 2008 | 2 | 0.020 |
Why?
|
Smoking | 3 | 1990 | 617 | 0.020 |
Why?
|
Pain | 2 | 1988 | 398 | 0.020 |
Why?
|
Safety | 2 | 2001 | 151 | 0.020 |
Why?
|
Axillary Vein | 1 | 1988 | 5 | 0.020 |
Why?
|
Acrylic Resins | 1 | 1988 | 22 | 0.020 |
Why?
|
Digestive System | 1 | 1988 | 42 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 1991 | 1083 | 0.020 |
Why?
|
Erythrocyte Count | 1 | 1988 | 22 | 0.020 |
Why?
|
Subclavian Vein | 1 | 1988 | 15 | 0.020 |
Why?
|
Arteries | 1 | 1989 | 180 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1989 | 498 | 0.020 |
Why?
|
Craniocerebral Trauma | 1 | 1988 | 54 | 0.020 |
Why?
|
Nursing Assessment | 1 | 2007 | 20 | 0.020 |
Why?
|
Diagnostic Tests, Routine | 1 | 1988 | 62 | 0.020 |
Why?
|
Privacy | 1 | 2007 | 20 | 0.020 |
Why?
|
Models, Organizational | 1 | 2007 | 47 | 0.020 |
Why?
|
Chlorides | 1 | 1988 | 103 | 0.020 |
Why?
|
Necrosis | 1 | 1988 | 210 | 0.020 |
Why?
|
Fishes, Poisonous | 1 | 1987 | 2 | 0.020 |
Why?
|
Carrier Proteins | 1 | 1991 | 679 | 0.020 |
Why?
|
Povidone | 1 | 1987 | 6 | 0.020 |
Why?
|
Povidone-Iodine | 1 | 1987 | 8 | 0.020 |
Why?
|
Length of Stay | 2 | 2002 | 722 | 0.020 |
Why?
|
Vehicle Emissions | 1 | 1986 | 3 | 0.020 |
Why?
|
Models, Biological | 1 | 1994 | 1764 | 0.020 |
Why?
|
Burns, Inhalation | 1 | 1986 | 4 | 0.020 |
Why?
|
Iodine | 1 | 1987 | 43 | 0.020 |
Why?
|
Triage | 1 | 2007 | 111 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2007 | 281 | 0.020 |
Why?
|
Methylprednisolone | 1 | 1986 | 66 | 0.020 |
Why?
|
Pressure Ulcer | 1 | 1987 | 42 | 0.020 |
Why?
|
Oxygen Inhalation Therapy | 1 | 1986 | 59 | 0.020 |
Why?
|
Quality Indicators, Health Care | 1 | 2007 | 146 | 0.020 |
Why?
|
Obstetric Labor, Premature | 1 | 1986 | 58 | 0.020 |
Why?
|
Transportation of Patients | 1 | 1986 | 32 | 0.020 |
Why?
|
Fibrinolytic Agents | 1 | 1988 | 209 | 0.020 |
Why?
|
Heart Rate | 1 | 1988 | 492 | 0.020 |
Why?
|
Botulinum Toxins, Type A | 1 | 2005 | 49 | 0.020 |
Why?
|
Heating | 3 | 1990 | 14 | 0.020 |
Why?
|
Coronary Disease | 1 | 1986 | 261 | 0.020 |
Why?
|
Lung | 1 | 1990 | 1241 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2007 | 414 | 0.010 |
Why?
|
Alcohols | 1 | 2003 | 15 | 0.010 |
Why?
|
Cyanides | 1 | 2003 | 16 | 0.010 |
Why?
|
Tracheostomy | 1 | 2003 | 44 | 0.010 |
Why?
|
Age Distribution | 1 | 2002 | 200 | 0.010 |
Why?
|
Encephalomyelitis, Venezuelan Equine | 1 | 2002 | 2 | 0.010 |
Why?
|
Tear Gases | 1 | 2002 | 2 | 0.010 |
Why?
|
Hemorrhagic Fevers, Viral | 1 | 2002 | 3 | 0.010 |
Why?
|
Cholera | 1 | 2002 | 6 | 0.010 |
Why?
|
Glanders | 1 | 2002 | 3 | 0.010 |
Why?
|
Ricin | 1 | 2002 | 6 | 0.010 |
Why?
|
Smallpox | 1 | 2002 | 6 | 0.010 |
Why?
|
Tularemia | 1 | 2002 | 8 | 0.010 |
Why?
|
Q Fever | 1 | 2002 | 8 | 0.010 |
Why?
|
Enterotoxins | 1 | 2002 | 20 | 0.010 |
Why?
|
T-2 Toxin | 1 | 2002 | 18 | 0.010 |
Why?
|
Brucellosis | 1 | 2002 | 13 | 0.010 |
Why?
|
Plague | 1 | 2002 | 27 | 0.010 |
Why?
|
Medical Audit | 1 | 2001 | 39 | 0.010 |
Why?
|
Parasympatholytics | 1 | 1999 | 19 | 0.010 |
Why?
|
Algorithms | 1 | 1988 | 1857 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2002 | 459 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2001 | 194 | 0.010 |
Why?
|
Drug Interactions | 1 | 1999 | 248 | 0.010 |
Why?
|
Extravasation of Diagnostic and Therapeutic Materials | 1 | 1999 | 15 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2001 | 454 | 0.010 |
Why?
|
Dobutamine | 1 | 1999 | 61 | 0.010 |
Why?
|
Injections, Subcutaneous | 1 | 1999 | 116 | 0.010 |
Why?
|
Suburban Population | 1 | 1998 | 6 | 0.010 |
Why?
|
Vasoconstrictor Agents | 1 | 1999 | 55 | 0.010 |
Why?
|
Acetone | 1 | 1998 | 6 | 0.010 |
Why?
|
Antiemetics | 1 | 1999 | 98 | 0.010 |
Why?
|
Fatty Acids, Nonesterified | 1 | 1998 | 69 | 0.010 |
Why?
|
Lead | 1 | 1998 | 26 | 0.010 |
Why?
|
Cardiotonic Agents | 1 | 1999 | 89 | 0.010 |
Why?
|
Venlafaxine Hydrochloride | 1 | 1997 | 4 | 0.010 |
Why?
|
Piperazines | 1 | 1999 | 280 | 0.010 |
Why?
|
Contraindications | 1 | 1997 | 71 | 0.010 |
Why?
|
Dopamine | 1 | 1999 | 275 | 0.010 |
Why?
|
Mice | 1 | 1991 | 11682 | 0.010 |
Why?
|
Heart Failure | 1 | 1986 | 1169 | 0.010 |
Why?
|
Triplets | 1 | 1995 | 8 | 0.010 |
Why?
|
Fluorescence Polarization | 1 | 1995 | 9 | 0.010 |
Why?
|
Financial Management, Hospital | 1 | 1995 | 4 | 0.010 |
Why?
|
Utilization Review | 1 | 1995 | 23 | 0.010 |
Why?
|
Twins | 1 | 1995 | 65 | 0.010 |
Why?
|
Quality Control | 1 | 1995 | 116 | 0.010 |
Why?
|
Organizational Policy | 1 | 1995 | 55 | 0.010 |
Why?
|
Intensive Care Units, Neonatal | 1 | 1995 | 69 | 0.010 |
Why?
|
Urban Population | 1 | 1995 | 223 | 0.010 |
Why?
|
Quality Assurance, Health Care | 1 | 1995 | 224 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 1998 | 2019 | 0.010 |
Why?
|
Tablets, Enteric-Coated | 1 | 1992 | 6 | 0.010 |
Why?
|
Serum Globulins | 1 | 1991 | 12 | 0.010 |
Why?
|
Rheumatoid Factor | 1 | 1991 | 24 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1991 | 271 | 0.010 |
Why?
|
Antibodies, Antinuclear | 1 | 1991 | 83 | 0.010 |
Why?
|
Immunoglobulin M | 1 | 1991 | 163 | 0.010 |
Why?
|
Tachycardia, Supraventricular | 1 | 1990 | 16 | 0.010 |
Why?
|
Substance Abuse, Intravenous | 1 | 1991 | 59 | 0.010 |
Why?
|
In Vitro Techniques | 1 | 1992 | 995 | 0.010 |
Why?
|
Hypercholesterolemia | 1 | 1991 | 159 | 0.010 |
Why?
|
Patient Compliance | 1 | 1991 | 228 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 1990 | 160 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 1996 | 1034 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 1991 | 466 | 0.010 |
Why?
|
Fractures, Closed | 1 | 1988 | 9 | 0.010 |
Why?
|
Sodium Hydroxide | 1 | 1988 | 5 | 0.000 |
Why?
|
Streptokinase | 1 | 1988 | 12 | 0.000 |
Why?
|
Physical Exertion | 1 | 1988 | 38 | 0.000 |
Why?
|
Nursing Staff, Hospital | 1 | 1988 | 42 | 0.000 |
Why?
|
Joint Dislocations | 1 | 1988 | 27 | 0.000 |
Why?
|
ROC Curve | 1 | 1990 | 773 | 0.000 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 1988 | 49 | 0.000 |
Why?
|
Rats, Inbred Strains | 1 | 1988 | 312 | 0.000 |
Why?
|
Gastric Mucosa | 1 | 1988 | 66 | 0.000 |
Why?
|
Warfarin | 1 | 1988 | 104 | 0.000 |
Why?
|
Wounds, Nonpenetrating | 1 | 1988 | 93 | 0.000 |
Why?
|
Syndrome | 1 | 1988 | 448 | 0.000 |
Why?
|
Risk | 1 | 1987 | 660 | 0.000 |
Why?
|
Clinical Trials as Topic | 1 | 1988 | 1141 | 0.000 |
Why?
|
Predictive Value of Tests | 1 | 1987 | 1703 | 0.000 |
Why?
|
Rats | 1 | 1988 | 4028 | 0.000 |
Why?
|
Internship and Residency | 1 | 1988 | 1036 | 0.000 |
Why?
|